Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.41 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.41 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetamide SCHEMBL28027672 | 0.96 | TSHR (0.47) | TSHRPKMEPHX2LMNAGRIN1 | |
| Methyl Alcohol SCHEMBL28225130 | 0.83 | TSHR (0.48) | TSHRPKMEPHX2LMNAGRIN1 | |
| SCHEMBL3190483 | 0.83 | GRIN1 (0.48) | TSHREPHX2LMNAGRIN1GRIN2A | |
| SCHEMBL733849 | 0.83 | GRIN1 (0.48) | TSHREPHX2LMNAGRIN1GRIN2A | |
| SCHEMBL28098347 | 0.81 | TSHR (0.50) | TSHREPHX2LMNAGRIN1GRIN2A | |
| SCHEMBL3821518 | 0.81 | TSHR (0.54) | TSHREPHX2GRIN1GRIN2AGRIN2D | |
| Methacrylic Acid SCHEMBL27410214 | 0.81 | TSHR (0.46) | TSHREPHX2LMNAGRIN1GRIN2A | |
| Bromide SCHEMBL4732099 | 0.80 | GRIN1 (0.46) | TSHRPKMEPHX2LMNAGRIN1 | |
| Hydrochloric Acid SCHEMBL28669825 | 0.80 | GRIN1 (0.50) | TSHREPHX2LMNAGRIN1GRIN2A | |
| SCHEMBL7452750 | 0.78 | TSHR (0.47) | TSHRLMNANPSR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115073304-A | Post-treatment preparation method of memantine hydrochloride | 北京云鹏鹏程医药科技有限公司 | 2022-09-20 | — | — | CN | claimed |
| EP-1836157-B1 | PROCESS FOR THE PREPARATION OF 1-AMINO-3,5-DIMETHYLADAMANTANE HYDROCHLORIDE | TEVA PHARM FINE CHEMICALS SRL (IT) | 2009-10-07 | — | — | EP | claimed |
| EP-1836157-A1 | PROCESS FOR THE PREPARATION OF 1-AMINO-3,5-DIMETHYLADAMANTANE HYDROCHLORIDE | Teva Pharmaceutical Fine Chemicals S.R.L. (IT) | 2007-09-26 | — | — | EP | claimed |
| US-20060173215-A1 | Process for the preparation of 1-amino-3,5-dimethyladamantane hydrochloride | TEVA PHARMACEUTICALS USA, INC. | 2006-08-03 | — | — | US | claimed |
| WO-2006076562-A1 | PROCESS FOR THE PREPARATION OF 1-AMINO-3,5-DIMETHYLADAMANTANE HYDROCHLORIDE | TEVA PHARMACEUTICAL FINE CHEMICALS S.R.L. (IT) | 2006-07-20 | — | — | WO | claimed |
| CN-115073304-A | Post-treatment preparation method of memantine hydrochloride | 北京云鹏鹏程医药科技有限公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-115073304-A | Post-treatment preparation method of memantine hydrochloride | 北京云鹏鹏程医药科技有限公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-104936942-A | Manufacturing process for memantine | MITSUBISHI GAS CHEMICAL CO | 2015-09-23 | — | — | CN | disclosed |
| EP-2555616-A1 | PROCESS FOR THE PREPARATION OF MEMANTINE HYDROCHLORIDE | Hetero Research Foundation (IN) | 2013-02-13 | — | — | EP | disclosed |
| WO-2011125062-A1 | PROCESS FOR THE PREPARATION OF MEMANTINE HYDROCHLORIDE | HETERO RESEARCH FOUNDATION (IN) | 2011-10-13 | — | — | WO | disclosed |
| EP-1836157-B1 | PROCESS FOR THE PREPARATION OF 1-AMINO-3,5-DIMETHYLADAMANTANE HYDROCHLORIDE | TEVA PHARM FINE CHEMICALS SRL (IT) | 2009-10-07 | — | — | EP | disclosed |
| EP-1836157-A1 | PROCESS FOR THE PREPARATION OF 1-AMINO-3,5-DIMETHYLADAMANTANE HYDROCHLORIDE | Teva Pharmaceutical Fine Chemicals S.R.L. (IT) | 2007-09-26 | — | — | EP | disclosed |
| US-20060173215-A1 | Process for the preparation of 1-amino-3,5-dimethyladamantane hydrochloride | TEVA PHARMACEUTICALS USA, INC. | 2006-08-03 | — | — | US | disclosed |
| WO-2006076562-A1 | PROCESS FOR THE PREPARATION OF 1-AMINO-3,5-DIMETHYLADAMANTANE HYDROCHLORIDE | TEVA PHARMACEUTICAL FINE CHEMICALS S.R.L. (IT) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173215-A1 | Process for the preparation of 1-amino-3,5-dimethyladamantane hydrochloride | HTR5A, HNMT, HTR1A | TSHR 3076/4885PKM 512/4885EPHX2 3113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.